Payment overview · 2025
General Payments
$260.85
10 reported records · 6 companies
Healthcare provider profile · identity verified
Jonathan Austin Henderson, MD
Allopathic & Osteopathic Physicians|Internal Medicine · GREENSBORO, NC · NPI 1720646920
Verified facts
What the public records show
CMS Open Payments records show Jonathan Austin Henderson, MD received $260.85 in general payments during 2025 across 10 reported records.
Xeris Pharmaceuticals, Inc. accounted for 37.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Shingrix.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 154 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 192 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $96.86 | 37.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $71.02 | 27.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.29 | 13.9% | 2 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $24.28 | 9.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $17.82 | 6.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $14.58 | 5.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $260.85 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KEVEYIS Normalized: keveyis |
Drug | Xeris Pharmaceuticals, Inc. | $96.86 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $52.31 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $52.31 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.29 | 2 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $24.28 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $17.82 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 11 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 192 | exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 75 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
75 | 57 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
154 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
93 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
192 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 792 | 225 |
| Atorvastatin Calcium | Atorvastatin Calcium | 644 | 194 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 601 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 360 | 86 |
| Losartan Potassium | Losartan Potassium | 346 | 106 |
| Lisinopril | Lisinopril | 256 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 74 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 73 |
| Telmisartan | Telmisartan | 199 | 53 |
| Eliquis | Apixaban | 192 | 47 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 66 |
| Omeprazole | Omeprazole | 187 | 65 |
| Sertraline Hcl | Sertraline Hcl | 187 | 50 |
| Gabapentin | Gabapentin | 185 | 52 |
| Allopurinol | Allopurinol | 180 | 51 |
| Alprazolam | Alprazolam | 180 | 49 |
| Metformin Hcl Er | Metformin Hcl | 180 | 58 |
| Simvastatin | Simvastatin | 163 | 54 |
| Metformin Hcl | Metformin Hcl | 159 | 54 |
| Jardiance | Empagliflozin | 154 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 151 | 27 |
| Furosemide | Furosemide | 143 | 56 |
| Trazodone Hcl | Trazodone Hcl | 138 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 46 |
| Carvedilol | Carvedilol | 122 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 39 |
| Potassium Chloride | Potassium Chloride | 112 | 35 |
| Spironolactone | Spironolactone | 108 | 30 |
| Clonazepam | Clonazepam | 107 | 25 |
| Prednisone | Prednisone | 106 | 68 |
| Boostrix Tdap | Diphth,pertuss(Acell),tet Vac | 105 | 105 |
| Lorazepam | Lorazepam | 100 | 28 |
| Ozempic | Semaglutide | 100 | 18 |
| Valsartan | Valsartan | 95 | 31 |
| Trulicity | Dulaglutide | 93 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 24 |
| Bupropion Xl | Bupropion Hcl | 89 | 24 |
| Glimepiride | Glimepiride | 89 | 29 |
| Tramadol Hcl | Tramadol Hcl | 88 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 21 |
| Famotidine | Famotidine | 86 | 28 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 85 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 79 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 24 |
| Ezetimibe | Ezetimibe | 78 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 76 | 23 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 75 | 57 |
| Alendronate Sodium | Alendronate Sodium | 73 | 19 |
| Meloxicam | Meloxicam | 67 | 26 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 24 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 62 | 18 |
| Xarelto | Rivaroxaban | 61 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 60 | 21 |
| Donepezil Hcl | Donepezil Hcl | 60 | 15 |
| Finasteride | Finasteride | 60 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 60 | 20 |
| Repatha Sureclick | Evolocumab | 60 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 58 | 21 |
| Testosterone | Testosterone | 57 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 55 | 15 |
| Memantine Hcl | Memantine Hcl | 49 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 18 |
| Atenolol | Atenolol | 46 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 46 | suppressed |
| Diazepam | Diazepam | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 35 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | 12 |
| Montelukast Sodium | Montelukast Sodium | 42 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 42 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Torsemide | Torsemide | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | 11 |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 33 | suppressed |
| Azithromycin | Azithromycin | 32 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 28 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 23 |
| Temazepam | Temazepam | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 26 | 21 |
| Glipizide Er | Glipizide | 26 | suppressed |
| Synthroid | Levothyroxine Sodium | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Estradiol | Estradiol | 24 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 23 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | 16 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Cephalexin | Cephalexin | 20 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 20 | suppressed |
| Eszopiclone | Eszopiclone | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Indomethacin | Indomethacin | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 16 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Fluocinonide | Fluocinonide | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 14 | suppressed |
| Eplerenone | Eplerenone | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Mupirocin | Mupirocin | 14 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Cholestyramine Light | Cholestyramine | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $260.85 · 10 records | Xeris Pharmaceuticals, Inc. | ABRYSVO, AREXVY, COMIRNATY, ELIQUIS, INSPIRE, KEVEYIS, MOUNJARO, NURTEC ODT, PRECIVITYAD2, PREVNAR 20, SHINGRIX, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error